Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025)
Collegium Pharmaceutical (COLL) posted Gains from Investment Securities of -$19000.0 for Q4 2025, little changed on a QoQ basis from -$19000.0 in Q3 2025, and up 99.35% year-over-year from -$9531.1 in Q4 2024.
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Collegium Pharmaceutical has reported Gains from Investment Securities for 2 years, with the latest figure at -$19000.0 in Q4 2025.
- On a quarterly basis, Gains from Investment Securities rose 99.35% year-over-year to -$19000.0 in Q4 2025; TTM through Jun 2026 was -$38000.0, a 99.06% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 59.44% from the prior year.
- Gains from Investment Securities was -$19000.0 for Q4 2025 at Collegium Pharmaceutical, roughly flat from -$19000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was -$19000.0 in Q3 2025, with the low at -$2.9 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -358,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Dec 31, 2024 | -2.91 Mn |